Cutaneous T-Cell Lymphoma: Disease, Diagnosis, and Therapy

What Is Cutaneous T-Cell Lymphoma (CTCL)?

MF and SS/L-CTCL Subtypes

CTCL Affects a Considerable Population, and Incidence Is Increasing

Etiology and Risk Factors for CTCL

WHO Classification 2016: T-Cell Lymphoma

Pathogenesis

Somatic Single Nucleotide Variants (SSNVs) 75% C > T Transitions

Mutations in Signal Transduction Pathways

Cytokine Expression and Cellular Changes in Early and Late Stages of MF/SS

Th1/Th2 Dichotomy in Progressive CTCL

Functional Polarization Suppresses Normal T-Cell Function and Induces Autocrine Proliferation

Development of T-Cell Clonality Assessment

PROCLIPI Study for MF and SS

PROCLIPI Study: Stage at Diagnosis (n = 693)

Clinical Features of MF

5-Year Survival Rates for MF and SS

Clinical Spectrum: Stages IA and IB

Clinical Spectrum: Stage IB

Patches, Plaques, and Tumors Occurring Simultaneously

Advanced-Stage MF

Key Histologic Features of MF: Histopathology

Key Histologic Features of MF: Immunophenotype

Histologic Features of MF

Folliculotropic MF

Distinct Subtypes of MF

Examples of MF Subtypes

Differential Diagnosis of MF

Defining Early MF

Initial Diagnosis of Suspected MF/SS

TNMB Classification of MF/SS: Current Recommendations

Clinical Staging of MF and SS: Current Recommendations

CTCL Is Associated With Significantly Reduced QoL

Patient-Reported Impact of CTCL

Goals of Therapy for Patients With CTCL in 2018

Due to Its Heterogeneity, CTCL Has No Single, Common Management Plan

Current Treatment Strategies for MF/SS Are Based on Disease Stage

EORTC Recommendations for First-Line Treatment of MF (Stages IA, IB, and IIA)

ESMO Recommendations for Treatment of MF

Interferon-α and Bexarotene

Interferon-α Mono- and Combination Therapy in Cutaneous Lymphomas

Combinations

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)